Utility of transcranial sonography in the diagnosis of drug-induced parkinsonism: A prospective study

European Journal of Neurology

Volumn 20, Issue 11, 2013, Pages 1451-1458

  Olivares Romero, J ^a   Arjona Padillo, A ^a   Barrero Hernandez F J ^b   Martin Gonzalez M ^a   Gil Extremera, B ^c  

^a HOSPITAL TORRECÁRDENAS   (Spain)

^b HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

Author keywords

Drug induced parkinsonism; Lentiform nucleus; Nigrostriatal pathway; Substantia nigra; Transcranial sonography

Indexed keywords

IOFLUPANE I 123; LEVODOPA;

ADULT; AGED; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE EXACERBATION; DRUG INDUCED DISEASE; ECHOENCEPHALOGRAPH; ECHOENCEPHALOGRAPHY; EDITORIAL; FEMALE; FISHER EXACT TEST; FOLLOW UP; HUMAN; IATROGENIC DISEASE; MALE; PARKINSONISM; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANTIA NIGRA; TRANSCRANIAL SONOGRAPHY; CHEMICALLY INDUCED; CORPUS STRIATUM; ECHOGRAPHY; MIDDLE AGED; PARKINSON DISEASE; STANDARDS; TRANSCRANIAL DOPPLER ULTRASONOGRAPHY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CORPUS STRIATUM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE, SECONDARY; SUBSTANTIA NIGRA; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 84885850825     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12131     Document Type: Editorial

References (30)

1. Munhoz RP, Werneck LC, Teive HA. The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 year comparison in tertiary movement disorders clinics. Clin Neurol Neurosurg 2010; 112: 431-435.
2. López-Sendón JL, Mena MA, de Yébenes JG. Drug-induced parkinsonism in the elderly: incidence, management and prevention. Drugs Aging 2012; 29: 105-118.
3. Bondon-Guitton E, Perez-Lloret S, Bagheri H, Brefel C, Rascol O, Montastruc JL. Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France. Mov Disord 2011; 26: 2226-2231.
4. Nguyen N, Pradel V, Micallef J, Montastruc JL, Blin O. Drug-induced Parkinson syndromes. Therapie 2004; 59: 105-112.
5. Shannon KM. Movement disorders. In Bradley WG, Daroff RB, Fenichel GM, Jankovic J, eds. Neurology in Clinical Practice, 4th edn. Madrid: Elsevier, 2005:2105-2152.
6. Shin HW, Kim MJ, Kim JS, Lee MC, Chung SJ. Levosulpiride-induced movement disorders. Mov Disord 2009; 24: 2249-2253.
7. Hambÿe AS, Vervaet A, Dethy S. FP-CIT SPECT in clinically inconclusive Parkinsonian syndrome during amiodarone treatment: a study with follow-up. Nucl Med Commun 2010; 31: 583-589.
8. Tinazzi M, Antonini A, Bovi T, et al. Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. J Neurol 2009; 256: 910-915.
9. Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M, Djaldetti R. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov Disord 2006; 21: 510-514.
10. Esper CD, Factor SA. Failure of recognition of drug-induced parkinsonism in the elderly. Mov Disord 2008; 23: 401-404.
11. Booij J, Speelman JD, Horstink MW, Wolters EC. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001; 28: 266-272.
12. Vlaar AM, Bouwmans A, Mess WH, Tromp SC, Weber WE. Transcranial duplex in the differential diagnosis of parkinsonian syndromes: a systematic review. J Neurol 2009; 256: 530-538.
13. Hernández Vara J, Rubiera del Fueyo M, Lorenzo Bosquet C, Castell Conesa J, Molina Cateriano CA, Rodríguez FM. Utilidad de la sonografía del parénquima cerebral en la enfermedad de Parkinson: estudio comparativo con 123I-FP-CIT SPECT. Med Clin (Barc) 2008;131:285-289.
14. Vlaar AM, de Nijs T, van Kroonenburgh MJ, et al. The predictive value of transcranial duplex sonography for the clinical diagnosis in undiagnosed parkinsonian syndromes: comparison with SPECT scans. BMC Neurol 2008; 8: 42.
15. Jabs BE, Bartsch AJ, Pfuhlmann B. Susceptibility to neuroleptic-induced parkinsonism - age and increased substantia nigra echogenicity as putative risk factors. Eur Psychiatry 2003; 18: 177-181.
16. Berg D, Jabs B, Merschdorf U, Beckmann H, Becker G. Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy. Biol Psychiatry 2001; 50: 463-467.
17. Venegas P, Miranda G, Silva MC. Estudio de correlación clínico-radiológica, sensibilidad y especificidad de eco-tomografía transcraneana en enfermedad de Parkinson y otros trastornos del movimiento. Rev Med Chile 2011; 139: 54-59.
18. Mahlknecht P, Stockner H, Kiechl S, et al. Is transcranial sonography useful to distinguish drug induced parkinsonism from Parkinson's disease? Mov Disord 2012; 27: 1194-1196.
19. Godau J, Berg D. Role of transcranial ultrasound in the diagnosis of movement disorders. Neuroimag Clin N Am 2010; 20: 87-101.
20. Walter U, Dressler D, Probst T, et al. Transcranial brain sonography findings in discriminating between parkinsonism and idiopathic Parkinson disease. Arch Neurol 2007; 64: 1635-1640.
21. Berg D, Seppi K, Behnke S, et al. Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. Arch Neurol 2011; 68: 932-937.
22. Stockner H, Sojer M, K KS, et al. Midbrain sonography in patients with essential tremor. Mov Disord 2007;22:414-417.
23. Walter U, Hoeppner J, Prudente-Morrissey L, Horowski S, Herpertz SC, Benecke R. Parkinson's disease-like midbrain sonography abnormalities are frequent in depressive disorders. Brain 2007; 130: 1799-1807.
24. Schweitzer KJ, Hilker R, Walter U, Burghaus L, Berg D. Substantia nigra hyperechogenicity as a marker of predisposition and slower progression in Parkinson's disease. Mov Disord 2006; 21: 94-98.
25. Spiegel J, Hellwig D, Möllers MO, et al. Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease. Brain 2006; 129: 1188-1193.
26. Kim JY, Kim ST, Jeon SH, Lee WY. Midbrain transcranial sonography in Korean patients with Parkinson's disease. Mov Disord 2007; 22: 1922-1926.
27. Hagenah JM, König IR, Becker B, et al. Substantia nigra hyperechogenicity correlates with clinical status and number of Parkin mutated alleles. J Neurol 2007; 254: 1407-1413.
28. Mena MA, de Yébenes JG. Drug-induced parkinsonism. Expert Opin Drug Saf 2006; 5: 759-771.
29. Behnke S, Double KL, Duma S, et al. Substantia nigra echomorphology in the healthy very old: correlation with motor slowing. Neuroimage 2007; 34: 1054-1059.
30. Wijnhoud AD, Franckena M, van der Lugt A, Koudstaal PJ, Dippel ED. Inadequate acoustical temporal bone window in patients with a transient ischemic attack or minor stroke: role of skull thickness and bone density. Ultrasound Med Biol 2008; 34: 923-929.